Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Supernus Pharmaceuticals, Inc. (SUPN) had Income from Continuous Operations of $-38.55M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$718.95M |
|
$-38.55M |
|
$74.56M |
|
$644.39M |
|
$781.24M |
|
$-62.28M |
|
$13.25M |
|
$-49.03M |
|
$-49.03M |
|
$-38.55M |
|
|
Income from Continuous Operations |
$-38.55M |
$-38.55M |
|
$-38.55M |
|
$-62.28M |
|
$-62.28M |
|
56.45M |
|
56.45M |
|
$-0.68 |
|
$-0.68 |
|
| Balance Sheet Financials | |
$644.18M |
|
$10.53M |
|
$808.47M |
|
$1.45B |
|
$338.17M |
|
-- |
|
$52.76M |
|
$390.93M |
|
$1.06B |
|
$367.38M |
|
$1.06B |
|
57.46M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|